Recombinant Human ADAMTSL1 protein, His-tagged
Cat.No. : | ADAMTSL1-7361H |
Product Overview : | Recombinant Human ADAMTSL1 protein(Q8N6G6-2)(Met1-His439), fused with His tag, was expressed in Insect Cells. |
- Specification
- Gene Information
- Related Products
Source : | Insect Cells |
Species : | Human |
Tag : | His |
Form : | Lyophilized from sterile 20mM Tris, 500mM NaCl, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. |
Molecular Mass : | The secreted recombinant human ADAMTSL1 consists of 422 amino acids and predicts a molecular mass of 47.1 KDa. The apparent molecular mass of the protein is approximately 48 Kda in SDS-PAGE under reducing conditions due to glycosylation. |
Protein Length : | Met1-His439 |
Endotoxin : | < 1.0 EU per μg of the protein as determined by the LAL method |
Purity : | > 95 % as determined by SDS-PAGE |
Storage : | Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents. |
Gene Name : | ADAMTSL1 ADAMTS-like 1 [ Homo sapiens ] |
Official Symbol : | ADAMTSL1 |
Synonyms : | ADAMTSL1; ADAMTS-like 1; C9orf94, chromosome 9 open reading frame 94; ADAMTS-like protein 1; ADAMTSR1; FLJ35283; punctin; punctin-1; ADAM-TS related protein 1; C9orf94; PUNCTIN; ADAMTSL-1; FLJ41032; FLJ46891; MGC40193; MGC118803; MGC118805; DKFZp686L03130; |
Gene ID : | 92949 |
mRNA Refseq : | NM_001040272 |
Protein Refseq : | NP_001035362 |
MIM : | 609198 |
UniProt ID : | Q8N6G6 |
Products Types
◆ Recombinant Protein | ||
ADAMTSL1-1146H | Recombinant Human ADAMTSL1 Protein, MYC/DDK-tagged | +Inquiry |
Adamtsl1-1532M | Recombinant Mouse Adamtsl1 Protein, Myc/DDK-tagged | +Inquiry |
ADAMTSL1-310H | Recombinant Human ADAMTSL1 Protein, GST-tagged | +Inquiry |
ADAMTSL1-311H | Recombinant Human ADAMTSL1 Protein, GST-tagged | +Inquiry |
ADAMTSL1-157H | Recombinant Human ADAMTSL1 Protein, HIS-tagged | +Inquiry |
◆ Lysates | ||
ADAMTSL1-001HCL | Recombinant Human ADAMTSL1 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (13)
Ask a questionADAMTSL1 protein can be studied using a range of biochemical techniques including immunoblotting and immunohistochemistry. Animal models of ADAMTSL1-related disorders can also be used to study the molecular mechanisms underlying these diseases and to test potential therapeutic strategies.
ADAMTSL1 protein may be a potential drug target for therapies aimed at treating disorders associated with abnormal extracellular matrix composition, such as Ehlers-Danlos syndrome. Targeting this protein may help normalize the extracellular matrix and improve symptoms associated with these disorders.
ADAMTSL1 protein levels in the blood or other bodily fluids may serve as a biomarker for EDS. Decreased levels of ADAMTSL1 protein are associated with certain types of EDS, such as the dermatosparaxis type. However, more research is needed to validate the specificity and sensitivity of ADAMTSL1 as a biomarker for EDS.
One limitation in using ADAMTSL1 protein as a biomarker or drug target is the limited understanding of its exact role in different tissues and diseases. Other factors such as genetic variation in the ADAMTSL1 gene, environmental factors, and other interactions with cellular processes may also affect its applicability in different populations. Additionally, more research is needed to fully validate its potential as a biomarker and drug target.
Mutations in the ADAMTSL1 gene are associated with several connective tissue disorders, including dermatosparaxis-type Ehlers-Danlos syndrome, which is characterized by lax skin, joint hypermobility, and abnormal scarring. ADAMTSL1 mutations are also associated with Geleophysic dysplasia, a rare genetic disorder characterized by short stature, skeletal abnormalities, and facial dysmorphisms.
At this time, there are no drugs or therapies specifically targeting ADAMTSL1 protein in development for EDS or other related conditions. However, research into potential therapeutic targets for EDS is ongoing, and future drugs or therapies may target ADAMTSL1 or related proteins.
Reduced levels of ADAMTSL1 protein in the blood or tissues have been found in individuals with dermatosparaxis-type Ehlers-Danlos syndrome, suggesting that it may serve as a diagnostic biomarker. However, further studies are needed to validate its use for diagnostic purposes.
Some potential therapeutic targets for ADAMTSL1-related disorders include the use of gene therapy to restore the production of functional ADAMTSL1 protein, the development of small molecule inhibitors or activators of ADAMTSL1 function, and the use of drugs that regulate collagen production or turnover.
ADAMTSL1 protein may be a potential therapeutic target for treating EDS. Targeting this protein could help normalize the ECM and improve tissue structure and function in individuals with EDS. However, more research is needed to determine whether this approach is clinically feasible and effective.
ADAMTSL1 protein has been implicated in several other diseases, including Marfan syndrome, aortic aneurysms, and hypertension. However, the exact role of ADAMTSL1 in these conditions is less well understood and requires further investigation.
ADAMTSL1 protein has potential applications in research and clinical settings. It may be used as a biomarker to identify connective tissue disorders such as Ehlers-Danlos syndrome. ADAMTSL1 protein may also be a potential therapeutic target for treating disorders associated with abnormal extracellular matrix composition.
ADAMTSL1 protein can be studied using a variety of methods, including Western blotting, immunohistochemistry, and enzyme-linked immunosorbent assays (ELISAs). Animal and cellular models of EDS may also be used to study ADAMTSL1 function and potential therapeutic targets.
A decrease in ADAMTSL1 protein levels may be indicative of connective tissue disorders such as Ehlers-Danlos syndrome. Therefore, measuring ADAMTSL1 protein levels in serum or other bodily fluids may be a useful diagnostic tool for these disorders.
Ask a Question for All ADAMTSL1 Products
Required fields are marked with *
My Review for All ADAMTSL1 Products
Required fields are marked with *
Inquiry Basket